Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2021 1
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Endothelial Cell-Selective Adhesion Molecule Contributes to the Development of Definitive Hematopoiesis in the Fetal Liver.
Ueda T, Yokota T, Okuzaki D, Uno Y, Mashimo T, Kubota Y, Sudo T, Ishibashi T, Shingai Y, Doi Y, Ozawa T, Nakai R, Tanimura A, Ichii M, Ezoe S, Shibayama H, Oritani K, Kanakura Y. Ueda T, et al. Among authors: nakai r. Stem Cell Reports. 2019 Dec 10;13(6):992-1005. doi: 10.1016/j.stemcr.2019.11.002. Stem Cell Reports. 2019. PMID: 31813828 Free PMC article.
Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ueda T, Fukushima K, Kusakabe S, Yoshida K, Suga M, Nakai R, Koike M, Hino A, Akuta K, Toda J, Nagate Y, Doi Y, Fujita J, Yokota T, Hosen N. Ueda T, et al. Among authors: nakai r. Leuk Res Rep. 2022 Feb 15;17:100294. doi: 10.1016/j.lrr.2022.100294. eCollection 2022. Leuk Res Rep. 2022. PMID: 35242526 Free PMC article.
[Sequential therapy with inotuzumab ozogamicin followed by CAR T-cell therapy for Philadelphia chromosome-negative acute lymphoblastic leukemia].
Mizutani Y, Kusakabe S, Fukushima K, Murakami H, Hamada M, Hasegawa C, Mizuta E, Yamaguchi Y, Nakai R, Kurashige R, Hino A, Ueda T, Fujita J, Miyamura T, Hosen N. Mizutani Y, et al. Among authors: nakai r. Rinsho Ketsueki. 2024;65(2):78-83. doi: 10.11406/rinketsu.65.78. Rinsho Ketsueki. 2024. PMID: 38448002 Japanese.
Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.
Nakai R, Fukuhara S, Maeshima AM, Kim SW, Ito Y, Hatta S, Suzuki T, Yuda S, Makita S, Munakata W, Suzuki T, Maruyama D, Izutsu K. Nakai R, et al. Clin Case Rep. 2019 Nov 15;7(12):2500-2504. doi: 10.1002/ccr3.2543. eCollection 2019 Dec. Clin Case Rep. 2019. PMID: 31893088 Free PMC article.